This first-in-human phase 1 study assesses the safety, tolerability, and clinical outcomes of bemdaneprocel in participants with Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Henchcliffe et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: